Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review

Postprandial Dysmetabolism: The Missing Link Between Diabetes and Cardiovascular Events?

(2013) David Bell et al.   Endocrine Practice

Motherhood, Apple Pie, Hemoglobin A1C, and the DCCT

(2013) Dace L. Trence et al.   Endocrine Practice

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Severe Hypoglycemia Predicts Mortality in Diabetes

(2012) P. E. Cryer   DIABETES CARE

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETES OBESITY & METABOLISM

A Crossover Comparison of Glycemic Variations in Japanese Patients with Type 1 Diabetes Receiving Insulin Glargine Versus Insulin Detemir Twice Daily Using Continuous Glucose Monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN)

(2012) Daisuke Tsujino et al.   Diabetes Technology & Therapeutics

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

(2012) Ib Jonassen et al.   PHARMACEUTICAL RESEARCH

A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction: A reanalysis of the HEART2D study

(2011) S. E. Siegelaar et al.   DIABETES CARE

Postprandial Hyperglycemia and Glycemic Variability: Should we care?

(2011) E. Standl et al.   DIABETES CARE

Hypoglycemia and Cardiovascular Risks

(2011) B. M. Frier et al.   DIABETES CARE

Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic Groups

(2011) Nathan R. Hill et al.   Diabetes Technology & Therapeutics

Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus

(2011) James H. O'Keefe et al.   MAYO CLINIC PROCEEDINGS

Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years

(2010) B. I. Jakisch et al.   DIABETIC MEDICINE

For debate.Glucose variability and diabetes complication risk: we need to know the answer

(2010) E. S. Kilpatrick et al.   DIABETIC MEDICINE

‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting

(2010) A. Ceriello et al.   DIABETIC MEDICINE

The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence

(2010) C. Nordin   DIABETOLOGIA

Glucose Variability; Does It Matter?

(2010) Sarah E. Siegelaar et al.   ENDOCRINE REVIEWS

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

(2010) S M Ocheltree et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

(2010) S. Arnolds et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes

(2009) E. S. Kilpatrick et al.   DIABETES CARE

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study

(2009) G. B. Bolli et al.   DIABETES CARE

Type 1 Diabetes Among Adolescents

(2009) Ashley M. Di Battista et al.   DIABETES EDUCATOR

Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature

(2009) L. Nalysnyk et al.   DIABETES OBESITY & METABOLISM

Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy

(2009) Daniela Bruttomesso et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps

(2009) Lakshmi G. Potti et al.   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients

(2008) A. Ceriello et al.   DIABETES

Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?

(2008) J. Bragd et al.   DIABETES & METABOLISM

In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine

(2008) D. Bruttomesso et al.   DIABETIC MEDICINE

A comparison of glycaemic variability in CSII vs. MDI treated type 1 diabetic patients using CGMS

(2008) B. Simon et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia

(2008) Assam El-Osta et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial*

(2008) Thomas Danne et al.   PEDIATRIC DIABETES

Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus

(2008) Lars Skogsberg et al.   PEDIATRIC DIABETES